Kartos Therapeutics logo
Science Research Advocacy About Contact Jobs

Our Clinical Research

Navtemadlin (KRT-232) Development
Kartos Science Pipeline 20250108a
Kartos-sponsored Trials

Myelofibrosis (MF) - POIESIS

Status: Recruiting

ClinicalTrials.gov: NCT06479135

Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Myelofibrosis (MF)

Status: Active, Not Recruiting

ClinicalTrials.gov: NCT04485260

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of Navtemadlin (KRT-232) Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib.

Myelofibrosis (MF) - BOREAS

Status: Active, Not Recruiting

ClinicalTrials.gov: NCT03662126

Navtemadlin (KRT-232) Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Myelofibrosis (MF)

Status: Active, Not Recruiting

ClinicalTrials.gov: NCT04878003

An Open-Label, Multicenter, Phase 2 Study Assessing the Safety and Efficacy of Navtemadlin (KRT-232) in Janus-associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Expanded Access Program

Expanded access, also known as “compassionate use,” refers to the use of an investigational agent outside of a clinical trial. This is a U.S. Food and Drug Administration (FDA) initiative that allows patients with serious illnesses, who have exhausted all other treatment options, the opportunity to access investigational agents that are not yet approved. It is important to remember that the safety and efficacy of these agents have not yet been established. Physicians and patients should discuss all possible benefits and risks before seeking expanded access to an investigational agent.

Kartos Therapeutics will evaluate each request for expanded access to KRT-232. All requests must be submitted to eap@kartosthera.com by a licensed healthcare professional. We will review the request promptly and respond within 48 hours.

For more information on the FDA Expanded Access program, please see the FDA website on Expanded Access, and/or talk to your healthcare provider.

Kartos Therapeutics logo

KARTOS THERAPEUTICS
is a clinical stage biopharmaceutical company with an investigational MDM2 inhibitor, navtemadlin (KRT-232)

275 Shoreline Drive, Suite 300
Redwood City, CA 94065

+1 650.542.0130 info@kartosthera.com
© 2025 Kartos Therapeutics Inc
  • Science
    • Navtemadlin
      (KRT-232)
  • Research
    • Clinical Trials
    • Expanded Access
  • Advocacy
  • About
    • Overview
    • Leadership
  • Contact
  • Jobs
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

© 2025 Kartos Therapeutics, Inc. All rights reserved. Terms of Use and Privacy Policy